导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.74% | 1345/4773 |
| 近一周 | -1.82% | 2939/5465 |
| 近一月 | -3.01% | 2095/5421 |
| 近一季 | -5.72% | 2166/5231 |
| 近半年 | -0.52% | 1498/4920 |
| 近一年 | 8.34% | 1335/4394 |
| 近两年 | 50.99% | 1460/2954 |
| 近三年 | 35.67% | 888/2253 |
| 成立以来 | 53.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.32% 1314/4961 |
12.17% 2215/5312 |
- - |
- - |
| 2025 | 18.94% 2267/4813 |
0.69% 1789/3635 |
2.66% 1445/4076 |
13.43% 2997/4524 |
1.45% 1377/4813 |
| 2024 | 16.33% 824/3463 |
4.28% 464/2808 |
0.29% 635/3014 |
14.76% 1914/3129 |
-3.07% 2251/3463 |
| 2023 | -9.48% 1171/2656 |
3.38% 1208/2280 |
-4.32% 1138/2385 |
-2.54% 690/2515 |
-6.11% 1629/2655 |
| 2022 | -20.08% 929/2207 |
-13.27% 722/1919 |
6.60% 651/2016 |
-12.76% 777/2113 |
-0.91% 1659/2208 |
| 2021 | 4.19% 588/1822 |
-0.47% 370/1255 |
6.92% 713/1330 |
-2.42% 571/1466 |
0.33% 1134/1822 |
| 2020 | 38.45% 359/1250 |
-10.28% 768/1028 |
14.90% 532/1067 |
20.38% 55/1164 |
11.56% 533/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 新华沪深300指数增强C VS. 长安沪深300非周期A(740101) |